AI Tokens
Stock Analysis on Net

UnitedHealth Group Inc. (NYSE:UNH)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

UnitedHealth Group Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Net earnings (loss) 4,300 5,670 6,481 218 2,543 3,572 6,474 5,784 6,258 4,421 (1,221) 5,675 6,038 5,657 5,774 4,908 5,384 5,199 5,148 4,191 4,191 4,372 4,978
Depreciation and amortization 1,073 1,040 1,029 1,117 1,099 1,084 1,061 1,041 1,041 1,020 997 974 1,007 1,021 970 982 828 802 788 771 796 778 758
Deferred income taxes 55 (129) 540 (733) (932) (151) 64 (62) 124 (331) (27) 249 (12) (150) (332) (83) (575) (176) 161 (243) 46 (14) 341
Share-based compensation 219 276 348 176 223 197 375 187 237 222 372 208 247 242 362 250 171 205 299 209 165 170 256
Loss on sale of subsidiary and subsidiaries held for sale 76 61 72 126 83 41 15 (21) 20 1,225 7,086 — — — — — — — — — — — —
Gains on dispositions and other strategic transactions — — — (910) — — — (3,333) — — — — — — — — — — — — — — —
Other, net (116) 69 (304) 1,609 (63) 30 97 582 (1,069) 280 179 (446) 32 (160) 69 (331) (215) 198 17 (749) 19 (159) (55)
Noncash items 1,307 1,317 1,685 1,385 410 1,201 1,612 (1,606) 353 2,416 8,607 985 1,274 953 1,069 818 209 1,029 1,265 (12) 1,026 775 1,300
Accounts receivable 1,079 5,025 (3,544) (829) 1,746 2,781 (4,462) (2,122) 3,156 3,691 (6,162) (540) (2,771) 4,503 (4,306) 40 1,641 317 (4,521) (153) 371 1,677 (2,895)
Other assets (1,284) 101 2,919 (1,501) (962) (1,599) (544) (1,152) 1,133 (2,194) (1,927) (86) (357) (126) (1,875) (633) (98) 446 (1,089) 404 88 (568) (955)
Medical costs payable 371 (716) 296 (354) 1,807 1,378 2,993 268 1,458 (1,292) 2,069 (355) 1,429 (59) 2,467 (139) 163 180 3,849 (1,224) 839 118 2,968
Accounts payable and other liabilities (1,064) 97 1,055 2,082 63 127 (607) 1,213 1,214 267 (231) 1,146 823 (249) 1,796 548 609 218 589 (9) 873 (572) 870
Unearned revenues 414 (442) 20 107 338 (272) (10) (16) 373 (563) 9 (12,018) 466 353 11,402 (10,075) 10,641 (518) 78 21 192 (262) (261)
Net change in other operating items, net of effects from acquisitions and dispositions (484) 4,065 746 (495) 2,992 2,415 (2,630) (1,809) 7,334 (91) (6,242) (11,853) (410) 4,422 9,484 (10,259) 12,956 643 (1,094) (961) 2,363 393 (273)
Cash flows from operating activities 5,123 11,052 8,912 1,108 5,945 7,188 5,456 2,369 13,945 6,746 1,144 (5,193) 6,902 11,032 16,327 (4,533) 18,549 6,871 5,319 3,218 7,580 5,540 6,005
Purchases of investments (6,420) (3,610) (6,515) (4,568) (4,625) (4,045) (4,135) (7,357) (9,821) (5,332) (4,798) (5,316) (3,773) (4,331) (4,894) (4,642) (5,280) (3,921) (4,982) (4,312) (3,980) (4,235) (4,612)
Sales of investments 2,630 786 1,878 1,343 2,764 1,996 3,185 3,449 9,777 2,312 2,976 3,633 486 2,732 456 531 3,028 757 1,591 4,476 1,161 765 643
Maturities of investments 2,055 2,425 2,285 1,929 2,191 2,159 2,167 2,581 2,117 2,307 2,314 2,756 2,011 2,344 2,119 1,341 1,551 1,430 1,759 1,695 1,906 2,395 2,255
Cash paid for acquisitions and other transactions, net of cash assumed (1,440) (98) — (73) (3,702) (32) (702) (1,734) (8,643) (25) (3,006) (1,747) (228) (335) (7,826) (14,304) (4) (5,919) (1,231) (94) (85) (3,449) (1,193)
Purchases of property, equipment and capitalized software (859) (799) (763) (948) (890) (886) (898) (912) (991) (853) (743) (959) (838) (829) (760) (866) (724) (657) (555) (695) (629) (562) (568)
Loans to care providers, cyberattack — — — — — — — (129) (804) (5,936) (2,164) — — — — — — — — — — — —
Repayments of care provider loans, cyberattack 85 115 82 137 250 402 891 1,325 2,585 604 — — — — — — — — — — — — —
Originations and purchases of loans (1,788) (1,530) (1,215) (1,513) (1,057) (1,392) (833) — — — — — — — — — — — — — — — —
Repayments and maturities of loans 877 725 699 986 406 334 254 — — — — — — — — — — — — — — — —
Cash received from dispositions and other strategic transactions, net 22 10 1,081 347 105 88 21 2,041 — — — 685 — — — 3,414 — — — — — — —
Other, net 265 178 21 (251) — (66) (24) (383) 129 (494) (919) (239) (297) (309) (115) (843) 582 (277) (255) (354) (252) (416) (232)
Cash flows used for investing activities (4,573) (1,798) (2,447) (2,611) (4,558) (1,442) (74) (1,119) (5,651) (7,417) (6,340) (1,187) (2,639) (728) (11,020) (15,369) (847) (8,587) (3,673) 716 (1,879) (5,502) (3,707)
Common share repurchases (3,385) (1,646) — — — (2,545) (3,000) (4,972) (956) — (3,072) (1,500) (1,500) (3,000) (2,000) (1,000) (1,000) (2,500) (2,500) (1,050) (1,050) (1,250) (1,650)
Cash dividends paid (2,078) (2,087) (2,005) (2,002) (2,002) (2,000) (1,912) (1,932) (1,937) (1,935) (1,729) (1,738) (1,739) (1,747) (1,537) (1,541) (1,542) (1,545) (1,363) (1,365) (1,367) (1,367) (1,181)
Proceeds from common stock issuances 240 128 231 24 222 221 360 235 867 258 486 314 411 284 344 169 328 205 551 278 313 328 436
Repayments of long-term debt (1,150) (1,000) (1,500) (1,050) (2,000) — — (500) (750) (1,000) (750) — — (750) (1,375) (915) (1,000) — (1,100) (1,250) — (750) (1,150)
Proceeds from (repayments of) short-term borrowings, net 2,888 (3,413) 1,100 (662) 2,872 (5,314) 3,911 40 (8,806) 2,426 6,189 (1,568) (1,847) (3,923) 7,349 748 (1,356) (1,808) 3,148 (1) (1,125) (4,233) 4,057
Proceeds from issuance of long-term debt — — — — — 2,969 — — 11,886 — 5,925 — — (7) 6,401 8,897 — 5,922 — (1) — 6,934 —
Customer funds administered (1,075) (268) 600 2,158 (1,767) (1,270) 1,245 (501) (2,049) (755) 1,745 (2,558) (2,032) (943) 5,012 (1,480) 1,242 666 5,120 (780) (993) 264 2,131
Purchases of redeemable noncontrolling interests — — — (165) — — — (280) — — — (730) — — — — (79) (97) — — — (1,338) —
Other, net 1,142 (337) (1,418) 666 (90) (8) (505) (432) (460) (190) (563) 624 (397) (373) (1,004) (486) (9) 103 (1,552) 542 (175) 1,194 (1,856)
Cash flows from (used for) financing activities (3,418) (8,623) (2,992) (1,031) (2,765) (7,947) 99 (8,342) (2,205) (1,196) 8,231 (7,156) (7,104) (10,459) 13,190 4,392 (3,416) 946 2,304 (3,627) (4,397) (218) 787
Effect of exchange rate changes on cash and cash equivalents (8) 4 (7) 15 (4) 14 15 (31) 14 4 (48) 48 (57) 55 51 30 (53) (100) 157 (17) (51) 57 (51)
Increase (decrease) in cash and cash equivalents, including cash within businesses held for sale (2,876) 635 3,466 (2,519) (1,382) (2,187) 5,496 (7,123) 6,103 (1,863) 2,987 (13,488) (2,898) (100) 18,548 (15,480) 14,233 (870) 4,107 290 1,253 (123) 3,034
Net change in cash within businesses held for sale 136 (51) 170 (326) (4) 66 (91) 35 11 (265) — — — — — — — — — — — — —
Net increase (decrease) in cash and cash equivalents (2,740) 584 3,636 (2,845) (1,386) (2,121) 5,405 (7,088) 6,114 (2,128) 2,987 (13,488) (2,898) (100) 18,548 (15,480) 14,233 (870) 4,107 290 1,253 (123) 3,034

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The financial data reveals a period of significant volatility in cash flows, characterized by substantial fluctuations in operating activities and strategic shifts in investing and financing behaviors. While net earnings generally remained positive and grew from 2021 through 2023, the subsequent periods exhibit sharp deviations attributed to non-recurring events and strategic structural changes.

Operating Cash Flow Dynamics
Cash flows from operating activities demonstrate extreme quarterly variance. A peak was observed in the third quarter of 2022 at 18.5 billion USD, contrasted by significant outflows in the fourth quarters of 2022 and 2023. This volatility is largely driven by swings in unearned revenues and other operating items. Accounts receivable and medical costs payable exhibit cyclical patterns, often offsetting each other, though large outflows in accounts receivable are noted periodically, particularly in the first quarters of several years.
Investing Activity and Capital Allocation
Investing activities are consistently characterized by net outflows, reflecting a strategy of continuous growth and asset acquisition. Expenditures for property, equipment, and capitalized software show a steady upward trajectory, rising from approximately 560 million USD per quarter in 2021 to over 850 million USD by late 2026. A massive outflow of 14.3 billion USD for acquisitions occurred in December 2022. More recently, beginning in March 2025, a new pattern of loan originations and purchases emerged, with quarterly outflows exceeding 1 billion USD.
Financing Strategy and Shareholder Returns
Financing activities indicate a disciplined approach to shareholder returns coupled with opportunistic debt management. Cash dividends paid have grown steadily from approximately 1.2 billion USD per quarter in 2021 to over 2 billion USD per quarter by 2026. Common share repurchases are executed sporadically and in varying magnitudes, with significant buybacks noted in the fourth quarter of 2024. The company utilizes both short-term and long-term debt to manage liquidity, evidenced by large periodic issuances of long-term debt, such as the 11.8 billion USD infusion in September 2024.
Analysis of Non-Recurring and Exceptional Items
Several anomalous events heavily impacted the cash flow profile. A substantial loss on the sale of subsidiaries totaling over 7 billion USD was recorded in March 2024, which contributed to a corresponding dip in net earnings. Additionally, a specific liquidity event related to a cyberattack is evident, with massive loan outflows to care providers in early 2024, followed by a gradual recovery of those funds through repayments over subsequent quarters.
Asset and Liability Management
Depreciation and amortization expenses have maintained a consistent growth trend, increasing from 758 million USD in March 2021 to 1.07 billion USD by September 2026, indicating an expanding base of depreciable assets. The management of investments shows a continuous cycle of purchases and sales, with a notable spike in investment sales and purchases in late 2024, suggesting a rebalancing of the portfolio.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?